8/103 sources · 2 publishersUpdated Oct 24, 11:13 UTC
Johnson & Johnson reports early-stage trial shows tumor shrinkage for experimental prostate cancer drug
Johnson & Johnson disclosed results from an early-stage study of its oral prostate cancer candidate JNJ‑6143. In 31 evaluable patients, 77% achieved PSA reductions of at least 50% and 69% showed confirmed tumor shrinkage. The drug was obtained through JNJ’s $3.05 billion acquisition of Halda Therapeutics. Safety signals included nausea and elevated cholesterol, with one discontinuation due to adverse effects.
Why it matters
The positive efficacy signals could increase the perceived value of JNJ’s oncology pipeline and may influence future investment in further trials, though no revenue impact is immediate.
Key facts
- 1The trial enrolled 31 evaluable patients receiving a 50‑mg dose of JNJ‑6143. investing.com
- 277% of patients experienced PSA reductions of at least 50%. investing.com
- 348% of patients recorded PSA declines of 90% or more. investing.com
- 469% of patients with measurable tumors achieved a confirmed complete or partial response. investing.com
- 5Johnson & Johnson acquired the drug through a $3.05 billion purchase of Halda Therapeutics. investing.com
- 6Reported side effects included nausea and elevated cholesterol and triglyceride levels. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.